BIOL Biolase Inc

Price (delayed)

$4.63

Market cap

$28.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.06

Enterprise value

$22.1M

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and ...

Highlights
BIOL's gross profit has soared by 145% year-on-year and by 12% since the previous quarter
The company's EPS has surged by 79% YoY and by 25% QoQ
Biolase's quick ratio has decreased by 48% YoY and by 17% from the previous quarter
The equity has decreased by 39% YoY and by 18% QoQ

Key stats

What are the main financial stats of BIOL
Market
Shares outstanding
6.17M
Market cap
$28.59M
Enterprise value
$22.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.39
Price to sales (P/S)
0.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.54
Earnings
Revenue
$41.24M
EBIT
-$11.93M
EBITDA
-$11.5M
Free cash flow
-$19.24M
Per share
EPS
-$2.06
Free cash flow per share
-$3.12
Book value per share
$3.34
Revenue per share
$6.7
TBVPS
$7.68
Balance sheet
Total assets
$50.24M
Total liabilities
$29.64M
Debt
$15.33M
Equity
$20.6M
Working capital
$30.67M
Liquidity
Debt to equity
0.74
Current ratio
3.34
Quick ratio
2.06
Net debt/EBITDA
0.56
Margins
EBITDA margin
-27.9%
Gross margin
44.9%
Net margin
-34%
Operating margin
-35.3%
Efficiency
Return on assets
-24.9%
Return on equity
-51.3%
Return on invested capital
-48.7%
Return on capital employed
-32.1%
Return on sales
-28.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIOL stock price

How has the Biolase stock price performed over time
Intraday
9.72%
1 week
1.54%
1 month
-7.03%
1 year
-74.8%
YTD
-52.51%
QTD
-47.57%

Financial performance

How have Biolase's revenue and profit performed over time
Revenue
$41.24M
Gross profit
$18.52M
Operating income
-$14.58M
Net income
-$14.03M
Gross margin
44.9%
Net margin
-34%
BIOL's gross profit has soared by 145% year-on-year and by 12% since the previous quarter
Biolase's revenue has soared by 58% YoY and by 5% from the previous quarter
Biolase's gross margin has soared by 55% YoY and by 6% from the previous quarter
The operating margin has surged by 52% year-on-year and by 16% since the previous quarter

Growth

What is Biolase's growth rate over time

Valuation

What is Biolase stock price valuation
P/E
N/A
P/B
1.39
P/S
0.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.54
The company's EPS has surged by 79% YoY and by 25% QoQ
BIOL's price to book (P/B) is 79% less than its 5-year quarterly average of 5.9 and 55% less than its last 4 quarters average of 2.8
The equity has decreased by 39% YoY and by 18% QoQ
The stock's price to sales (P/S) is 71% less than its last 4 quarters average of 2.2 and 48% less than its 5-year quarterly average of 1.2
Biolase's revenue has soared by 58% YoY and by 5% from the previous quarter

Efficiency

How efficient is Biolase business performance
BIOL's ROE has soared by 58% YoY and by 2.8% QoQ
The company's return on sales has surged by 50% YoY and by 18% QoQ
The return on assets has increased by 39% year-on-year and by 8% since the previous quarter
Biolase's ROIC has increased by 32% YoY and by 15% from the previous quarter

Dividends

What is BIOL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIOL.

Financial health

How did Biolase financials performed over time
The company's total assets is 69% higher than its total liabilities
Biolase's quick ratio has decreased by 48% YoY and by 17% from the previous quarter
The current ratio has declined by 35% year-on-year and by 6% since the previous quarter
BIOL's debt is 26% smaller than its equity
The equity has decreased by 39% YoY and by 18% QoQ
The debt to equity has increased by 37% YoY and by 23% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.